
Antibiotics
Latest News

Latest Videos

CME Content
More News

Stephanie Spivack, MD, discusses an upcoming healthcare provider symposium that will provide education around treating novel infections for patients with substance use disorder (SUD).

With spring here and tick bites on the rise, Andrew Handel, MD, provides tips on prevention as well as when to consider medical care for a bite.

The growing incidence of resistant Gram-negative infections in hospitals is being fueled by evolving resistance mechanisms, antibiotic overuse, and the rapid global spread of mobile genetic elements. Mariana Castanheira, PhD, FIDSA, FAAM, chief scientific officer at JMI Laboratories, discusses this topic and an agent with utility against pathogens carrying Metallo-beta-lactamases (MBLs).

Eolas Medical has an AI-powered clinical platform looking to aid health care professionals in accessing localized antimicrobial guidelines instantly, improving prescribing accuracy, reducing errors, and strengthening patient safety. CEO Declan Kelly, MBBS, provides insights on the platform and how his company is trying to address gaps in antimicrobial stewardship.

Mortality rates from treatment-resistant gram-negative infections remain high despite increased use of newer antibiotics and corresponding susceptibility testing.

New real-world data from the CIRCE study underscore cefiderocol’s potential in treating metallo-beta-lactamase–producing Enterobacterales infections, particularly among critically ill and immunocompromised patients with limited therapeutic options. Christine Slover, PharmD, offers some insights around the study and these infections.

A major international study reveals that World Health Organization-recommended first-line antibiotics are effective in only one in four neonatal sepsis infections in low- and middle-income countries, underscoring the growing threat of antimicrobial resistance.

AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.

In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.

Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.

A new meta-analysis finds alarming increases in colistin resistance among Acinetobacter baumannii and Pseudomonas aeruginosa across Africa, threatening the effectiveness of one of the last-resort antibiotics.

The World Health Organization has released 3 new target product profiles aimed at guiding the development of urgently needed antibiotics for severe drug-resistant infections, including multidrug-resistant gram-negative infections, resistant gram-positive infections in vulnerable patients, and bacterial meningitis.

Peptilogics has enrolled the first patient in its RETAIN trial evaluating PLG0206, a first-in-class anti-biofilm therapy designed to treat prosthetic joint infections.

Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardization and evidence remain.

In 2025, the Infectious Diseases Society of America published the first part of an update to the clinical practice guideline on the diagnosis and management of GAS pharyngitis. Here is an overview of the risk assessment and antibiotic treatment of GAS pharyngitis.

Ceftolozane-tazobactam cure rate for multidrug-resistant Pseudomonas aeruginosa infections is higher than with aminoglycosides/polymyxins and comparable to ceftazidime-avibactam.

This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.

The Centers for Disease Control and Prevention (CDC) characterizes epidemiology, serotype and treatment resistance of extraintestinal invasive Escherichia coli, the most common pathogen in community-onset sepsis.

A large international study published in The Lancet shows that obesity substantially increases the risk of severe illness and death from most infectious diseases, potentially accounting for more than 10% of infection-related deaths worldwide.

This week, listen in on commentary around the ongoing measles outbreak, read our new Antibiotics Deconstructed column on IV fosfomycin, review data on metformin preventing long COVID, insights on diagnostic stewardship, and more.

The FDA recently approved intravenous fosfomycin (Contepo), which is a new option for adults with complicated urinary tract infections, including those caused by resistant Gram-negative pathogens. Here is an overview of the therapeutic including its mechanism of action, data, availability, and prospective costs.

This is the fourth time the antimicrobial bill looking at a subscription-payment model has been introduced in the Congress and has some updates in how these therapeutics are developed and paid for with help from the federal government.

A global review finds growing antimicrobial resistance among the main bacteria causing meningitis—especially in low- and middle-income countries—raising concerns about the continued effectiveness of standard treatments and the urgent need for stronger surveillance.

MicuRx Pharmaceuticals has received FDA clearance to begin a phase 2a clinical trial of MRX-5, a novel oral antibacterial therapy for patients with Mycobacterium abscessus pulmonary disease.























































































